Background: Chronic rhinosinusitis with and without nasal polyps (CRSwNP and CRSsNP respectively) can be difficult to treat and biologics offer potential as a future therapeutic intervention. CRS and severe asthma often co-exist. Omalizumab is currently licenced for the treatment of severe allergic asthma.
Introduction
Chronic rhinosinusitis (CRS) is an umbrella term for a group of heterogeneous diseases featuring inflammation of the nose and sinuses. It can be further sub-classified into those with or without nasal polyps (CRSwNP and CRSsNP respectively) (1) . Sinus disease is found in nearly 90% of mild to moderate asthmatics and in up to 100% of severe steroid-dependent asthmatics as evidenced on sinonasal imaging (2) , emphasising the considerable burden this syndrome can place on healthcare resources and reduction in quality of life. CRS associated with asthma pheno-endotypes often demonstrate, in the broadest sense, a common immune signature defined by Th2 T cell predominance (3) . The hallmarks of such T2 inflammation includes interleukin (IL)-5 driven eosinophil recruitment and survival, IL-4 induction of immunoglobulin E (IgE) synthesis and IL-13 augmenting this Th2 driven inflammation. Serum IgE is a reflection of excess unbound tissue IgE in washout blood and secreted IgE from circulating IgE+ plasma cells (albeit a smaller proportion) (4) .
Studies have shown that blood eosinophilia correlates with high tissue eosinophilia in CRS (5) and patients with both high blood IgE and eosinophils have a more aggressive disease phenotype resistant to treatment (6, 7) . Furthermore, individuals who have
CRSwNP have been shown to have elevated tissue IgE and eosinophils (8) . This is consistent with the one airway hypothesis as asthma often coexists; severe asthmatics tend to have high serum eosinophil counts and IgE together (9) , reflecting the same immunopathological process occurring throughout the airway.
High levels of these blood biomarkers indicate high T2 inflammatory tissue states, and are used in severe asthma treatment protocols to select patients for more precise target specific treatment using IgE inhibition and eosinophil depletion strategies respectively.
Omalizumab (Xolair® Novartis) is an anti-IgE monoclonal IgG1
antibody licenced for therapeutic use in severe allergic asthma.
It binds to free serum IgE. The site of binding at the Ce3 domain prevents the interaction of IgE with FceRI via steric hindrance, preventing mast cell and basophil activation and degranulation (10) . There is subsequent downregulation of FcεRI due to the decrease in free IgE levels (11) . Omalizumab also prevents IgE binding to the low affinity IgE receptor CD23 on B cells and antigen-presenting cells (10) . A consequence of blocking this IgE mediated cell signalling is a decrease in IL-5 production (12) and cellular release. Hence recruitment of bone marrow derived eosinophils into blood and tissue sites is decreased as is eosinophil survival resulting in eosinophil depletion (13) (14) (15) . Thus with time the T2 inflammatory axis is downregulated (16) .
In the UK, currently only those with a raised blood IgE within a set range matched for body weight and a clearly identifiable perennial aeroallergen with severe allergic asthma can be treated with omalizumab. We previously reported our real-life experience with a group of n=13 severe allergic asthmatic patients with co-existent CRSwNP successfully treated with omalizumab (17) . Briefly our findings were that both CRSwNP and asthma improved in parallel, with the improvement in CRSwNP comparable to functional endoscopic sinus surgery with polypectomy at their 16-week follow-up. All the CRSwNP patients demonstrated raised total blood IgE and a significant proportion also had a raised eosinophil count (despite at least 4 courses of oral steroids to stabilise their asthma within the 12 months prior to omalizumab 
Materials and Methods

Ethics approval and consent to participate
This study did not require ethics approval or consent as the data was collected prospectively as part of the clinical assessment of asthma and is presented in an anonymised manner.
.
Availability of data and material
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
A cohort of patients with severe allergic asthma as defined in the ERS/ATS published criteria underwent detailed upper airway assessment as part of an asthma investigation protocol (18) . All were sensitised to common perennial aeroallergens. Based on direct nasal endoscopic examination and clinical history, patients were defined as either having allergic CRSsNP or CRSwNP.
The UK prescribing criteria for omalizumab in severe refractory 
Statistical analysis
Data is expressed as the median (range) or standard error (SE) as stated. All paired within-subject data was analysed using the diagnosis of CRSwNP (on the assumption more severe patients will respond better to omalizumab), and dosage regimen in terms of both injection frequency and drug amount.
As the IgE and eosinophil values were found to be non-normally distributed, these parameters were split into two groups. For IgE values, <200 (baseline) and ≥200 IU/mL were used, whilst for eosinophil values <150 (baseline) and ≥150 cells/ µL were used.
These cut-off points were taken from previously published reports (19, 20) . 
Results
The patient demography is summarised in Table 1 . In total, complete data sets were available for 25 patients with CRS and severe allergic asthma (n=10 with allergic CRSsNP and n=15
with CRSwNP). Of this group n=9 patients were on prednisolone at treatment entry till the 16-week assessment visit. Table 2 summaries the predictor variables included in the linear model analysis. given as either median ± SE or absolute patient numbers with percentages of the overall group size to having a count of <150 cells/ µL ( Figure 1B 
Discussion
Our real-life observations confirm that omalizumab improves sinonasal outcomes in patients with high-T2 inflammatory CRS pheno-endotypes. Despite patient selection in severe allergic asthma and CRS for omalizumab being purely based on the blood total IgE level, with sensitisation to at least one perennial aeroallergen being present, our analysis suggests that the biomarker of blood eosinophil count, rather than blood IgE total level, is a better predictor of treatment response to omalizumab in CRS.
Given the rapidly emerging market of biologics for T2 high asthma syndromes and CRS, being able to predict response to biologic therapy is essential. The aim of such 'precision medicine' is to target patients with a drug that will work to improve treatment outcomes quickly but also constrain costs by preventing wastage of agents and delivery resources. Biomarker guided therapy may help identify such CRS specific, treatment responsive subgroups. Our finding of blood eosinophil counts as opposed to total blood IgE predicting treatment response to omalizumab in CRS is consistent with other asthma omalizumab treatment studies. These also show an improved treatment response in relation to eosinophil counts, rather than just IgE levels (21, 22) . to either pollens or perennial allergens (23) . Omalizumab efficacy in non-allergic asthma, urticaria and eosinophilic oesophagitis further emphasises its ability to modulate complex immune cascades in so called 'non-allergic states' (24) (25) (26) (27) .
Omalizumab treatment leads to both blood and tissue eosinophil levels to rapidly reduce as previously stated. Our findings that patients with high blood eosinophils have a better clinical response to omalizumab are therefore not totally unexpected.
Eosinophils or at least IL-5 clearly have a role in the pathogenesis of CRS as shown by IL-5 blockade studies with mepolizumab (28, 29) . Another point worth considering is the effect of low dose prednisolone in patients with CRS and asthma and their clinical response to omalizumab. Prednisolone can modulate immune responsive factors, such as preventing eosinophilic exacerbations and this may have worked to modulate the benefits of omalizumab. Unfortunately, given our low patient numbers, with recurrent prednisolone use before omalizumab, it is difficult to delineate the exact nature of such prednisolone and omalizumab interactions on the clinical response. We stress this is real-life data, and some patients will always need treatment combinations.
As far as we are aware, specific IgE levels to an aeroallergen does not predict the efficacy of omalizumab treatment. Given that blood IgE does not reflect tissue IgE concentrations (4, 8) , and What is more difficult to explain is the finding that more frequent omalizumab dosing led to a better CRS treatment outcome. Twice monthly dosing has been shown to be efficacious in difficult urticaria (30) . At present we can only speculate and may have something to do with the pharmacokinetics of IgE interaction with its receptor. The current literature confirms that it is when omalizumab lowers unbound blood free IgE to less than 20 IU/ml that clinical benefit is seen in allergic asthmatic patients (31) . Omalizumab reduces serum-free IgE in a dose-related manner (32) . With this in mind, dosing protocols have been developed using information gleaned from complex pharmacodynamic modelling approaches, in order for the optimal level of IgE inhibition to be achieved and ensure all free blood IgE is bound and 'inactivated' by omalizumab. However, as the serum elimination half-life of omalizumab averaged 26 days (33) and the half-life of IgE binding to FceRI is 14-21 days, half the IgE is free after this time to bind new receptors and potentially re-initiate immune inflammatory cascades (34, 35) . Thus, injecting omalizumab at 2 weekly intervals may capture this newly released IgE and prevent re-FceRI binding. Another explanation could be through the allosteric actions of omalizumab on IgE where higher levels of omalizumab can lead to a phenomenon termed accelerated dissociation (36) . 
Conclusion
In conclusion we report that omalizumab can improve CRS outcomes where there is a high T2 inflammatory disease signal of raised blood eosinophils present. It is not necessarily disease severity that predicts treatment response as having CRSwNP (i.e. more severe symptoms) alone did not seem to be associated with clinical improvement. Our understanding of disease-relevant biomarkers and dosing regimens that best predict treatment response to biologics in CRS is clearly at an early stage.
Further studies are needed, and it is essential that researchers study pheno-endotypes with broader multiple overlapping biomarker groups when testing the efficacy of biologics. This will ensure that large cohorts of potentially treatment responsive patients are not excluded from such therapeutic approaches, as currently is the case. Studies must also look at long term treatment efficacy and any reduced need for surgery. Important questions to answer will be whether biologics will be an alternative treatment to surgery or used in conjunction with surgery to prevent disease recurrence. In addition, the health economics of treating associated multisystem disease such as CRS and asthma with one treatment must be carefully considered. Only then can precision medicine be delivered in an effective and cost-constrained manner (37) . Individual data points represent SNOT-22 scores of individual patients in each predictor variable group at the 16th week of omalizumab treatment.
